We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
thank you DOOM, must admit i have never seen the news on WHO?
thank you once again !!
@Blubutton
From the AGM :
In terms of our Global Health Division, we remain optimistic about the long-term prospects for the roll-out of our VISITECT® CD4 Advanced Disease test, the first and the world's only instrument-free point of care test for monitoring CD4 levels, essential for the effective management of advanced HIV. We have received excellent feedback from external clinical studies and evaluations in key countries and can see positive indications that long term funders are supporting the roll out of the Advanced Disease initiative. We therefore remain confident that the market potential for our product reaching 4m to 6m tests a year within the next three to five years, representing an opportunity to generate £12m to £18m in annualised revenues.
( £12m to £18m per year )
Yes I agree in the meantime it would be nice
to see the Home use RNS and sales order RNS
coming in quick succession for those that are un invested…..Trick or treat : )
"In order save lives, improve livelihood and promote stability, wouldn’t it be necessary for the company to actually supply something, rather than just pointless dialogue?"
Amen to that............................
“Don’t forget we are invested in a company that a time of a health crisis , we should remember that these kinds of investments not only save lives, improve livelihoods, and promote stability in some
of the poorest areas in the world .”
In order save lives, improve livelihood and promote stability, wouldn’t it be necessary for the company to actually supply something, rather than just pointless dialogue?
to be honest DOOM that's great, but we need substance, actual news, rather than speculation and rhetoric
WHO 3 year contract due anytime? where did that come from?
most of us were awaiting news on the DHSC 2 year contract ;)
https://www.nytimes.com/2021/07/15/health/covid-hiv-risk-study.html
CD4 testing never more important.
WHO news of 3 year deal with ODX due at anytime.
Don’t forget we are invested in a company that a time of a health crisis , we should remember that these kinds of investments not only save lives, improve livelihoods, and promote stability in some
of the poorest areas in the world .
Well done to all the longterm holders .